Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

PET Prostate Scan Volumes See Robust Growth in 2022 according to IMV’s 2023 PET Market Summary Report


IMV’s 2023 PET Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, radiopharmaceutical usage and site operations characteristics. The report was published in March 2023 and is based on responses from 386 radiology/departmental administrators and clinicians who participated in IMV’s nationwide survey from August 2021-September 2022. Vendors covered in this report include Bracco, Canon, Cardinal Health, GEHC, Jubilant, Philips, Siemens and SOFIE. The finding summaries follow.

PET prostate scan volumes increased 46% year-over-year, showing an increase of 3 percentage points to 9% of the overall procedure mix by study type, according to the newly published IMV 2023 PET Market Summary Report.

After a 12.2% increase in overall PET scan volume in 2021, PET scan volume remained flat year-over-year in 2022. However, the change in volume of PET scans varied by site type, with less than 400 bed hospitals having a 25% increase in scan volume, non-hospital sites seeing a 10.9% decrease and 400+ bed hospitals remaining flat in 2022.

Looking ahead, 47% of PET imaging sites anticipate their scan volumes will increase over the next 12 months, 44% volumes to stay the same and 1% anticipate a decrease.

Pertaining to radiopharmaceutical usage, 82% of PET scans used F-18-FDG, 7% used Rb-82 and all other agents made up the remaining 11%.

In 2022, 30% of sites were considering the purchase of a PET scanner over the next three years. Of planned system purchases in 2022, 92% will be equipped with a digital detector. The top OEMs being considered for future PET system purchases are Siemens with 64% of mentions, GEHC with 54%, Philips with 8%, Canon with 4% and United Imaging with 2%.

Regarding patient wait times for non-emergency outpatient PET scans, the overall median wait time is 6 days, with 29% of sites having a median wait time of less than 3 days. Independent PET sites have the shortest median wait time of 3 days, and 400+ bed hospitals, less than 200 bed hospitals and hospital-owned PET centers have the longest, with a median wait time of 7 days.

Want to share your knowledge of medical imaging? Click here to sign up for the IMV Survey Panel today.

For information about purchasing IMV Market Outlook Reports, visit the corporate website at https://imvinfo.com/ or call 703-778-3080 ext. 1033 to speak with a representative. In addition to the report, all purchases will include a complimentary recording of an executive summary presentation of findings conducted by IMV’s Senior Program Manager.

Disclosure: IMV Medical Information Division is a sister company of AuntMinnie.com.

Share article on social media or email:

Proem Behavioral Health to Exhibit at Rx and Illicit Drug Summit


Proem Behavioral Health will meet with attendees of the Rx and Illicit Drug Summit on April 10-12 to discuss how the company’s workflow engine helps practitioners treat SUD and mental illness.

“We have designed the Proem solution to make it easier for SUD providers to track, trend and measure patient outcomes and share vital progress reports with their patients,” said Proem CEO John Letter.

Proem Behavioral Health, developer of the evidence-based clinical workflow software engine that helps substance use disorder (SUD) clinics assess SUDs and mental illness to help achieve verifiable outcomes, invites attendees of the 2023 Rx and Illicit Drug Summit in Atlanta on April 10-12 to visit Proem Booth 142.

The intelligent workflow engine from Proem easily integrates into the workflow of SUD practitioners to simultaneously assess SUDs and the most common adult and pediatric mental disorders. This allows practitioners to effectively identify, diagnose, treat and monitor SUD and the underlying mental health disorders that often cause people to self-medicate with drugs and/or alcohol.

By using Proem, providers are more likely to make the right diagnosis the first time. For SUD practitioners, this gives peace of mind that they have a comprehensive picture of their patient so they can treat the whole person, not just the drug or alcohol dependence, and provide the proof of progress that’s essential for keeping patients engaged in their treatment and on a path to recovery.

Key features of the Proem solution include the following:

  • Evidence-based measurements and scales designed to fit seamlessly within a SUD practitioner’s existing workflow.
  • Multi-dimensional screeners and assessments that evaluate multiple mental illnesses to identify root causes of substance use.
  • Outcome and severity measurement tools that help practitioners adjust treatments when they are not working or continue those that are working.
  • Data collected at every step of the process to provide the documentation needed to demonstrate verifiable patient outcomes to providers, patients and payers.

“At Proem, we understand the challenges SUD clinics and practitioners face when working to help their patients overcome addiction and take better control of their lives,” said Proem CEO John Letter. “We have designed the Proem solution to make it easier for SUD providers to track, trend and measure patient outcomes and share vital progress reports with their patients. The Rx and Illicit Drug Summit meeting provides us an opportunity to show attendees how our solution is helping clinics and practitioners support individuals with SUD and mental illness and why we believe ‘healthy minds start with Proem.'”

ABOUT PROEM BEHAVIORAL HEALTH

Proem Behavioral Health provides the premier clinical workflow software engine that helps substance use disorder clinics, behavioral health providers and research organizations efficiently and accurately screen, test, and measure treatment success for those suffering from mental illness. Proem is the exclusive digital licensee worldwide of gold-standard, evidence-based screening solutions, structured interviews and post-diagnosis severity measurement scales to monitor patient outcomes. To learn more, visit proemhealth.com and follow Proem on LinkedIn and Twitter.

Share article on social media or email:



CS Analytical to Host Laboratory Tours and Client Meeting Program During NYC Interphex Week


News Image

While we routinely host client audits, the fact that Intephex is just around the corner enables us an opportunity to offer client tours and meetings for those contacts that are not local to our facility.

CS Analytical Laboratory, the world’s only cGMP, FDA-registered and inspected contract laboratory exclusively designed and dedicated to package and container testing for the pharmaceutical, biotechnology, and medical device industries, in conjunction with the New York Interphex Show scheduled for April 25th through April 27th, will host an open house and laboratory tour program for visiting clients. Clients coming to the New York Metropolitan area for Interphex will have the opportunity to schedule meeting time slots at the CS Analytical Laboratory. With a state of the art laboratory that features the most up to date instrumentation and electronic quality system processes, Interphex week, provides an ideal setting for clients to see in person the CS Analytical facility and meet its team members to discuss current and future container and package system testing needs.

“There is no other contract service provider within the FDA regulated community that is exclusively dedicated to container and package system qualification testing,” commented Sandra Cincotta, Director of Quality. “We have built out a laboratory facility that is designed to meet all USP and EP routine qualification testing requirements, can develop and validate methods specific to all of the current USP 1207 technologies for container integrity testing, and implemented a custom designed electronic quality system. While we routinely host client audits, the fact that Intephex is just around the corner enables us an opportunity to offer client tours and meetings for those contacts that are not local to our facility.”

Intephex will take place in New York City at the Jacob Javits Convention Center located on 34th street on the West Side of Manhattan. CS Analytical is located 12.6 miles due west through the Lincoln Tunnel, directly off Route 3 West. The drive from the show to the CS Analytical Laboratory will only take approximately 20-25 minutes. Onsite meetings at Interphex and Laboratory Tours may be may be pre-scheduled using the following link: https://engage.csanalytical.com/interphex

About CS Analytical Laboratory

The world’s only cGMP, FDA-registered contract laboratory exclusively designed and dedicated to container testing for the pharmaceutical, biotechnology, and medical device industries, the CS Analytical Team includes world-leading experts and thought-leaders on FDA and EU regulatory expectations and USP and EP primary package testing requirements inclusive of container closure integrity (CCI) testing (CCIT). Test services include CCI method development, validation, and analysis, USP/EP/JP physical and physicochemical testing, and Comprehensive and Complementary services for all common or unique primary packaging components and systems inclusive of glass, plastic, elastomeric, and more. CS Analytical is the single source to ensure a regulated industry product-package system meets strict, complex, and ever-changing regulatory requirements.

Share article on social media or email:

SAC Health Announces Major Grant to Expand Services to Help Improve Quality of Life for Inland Empire Residents


SAC Health Building and San Bernardino Campus

SAC Health – San Bernardino Campus

We have seen first-hand, how effective it is in helping individuals who have the most complex healthcare needs. Thanks to the California Department of Health Care Services and IEHP, SAC Health will be able to expand access to Enhanced Care Management for our patients. – Jason Lohr, CEO

SAC Health announced the award of a $2.139 million grant from the California Department of Health Care Services that will help increase the healthcare management of those who are in most need throughout the region. Through the following programs: ​California Advancing and​Innovating Medi-Cal (CalAIM) Initiative; Providing Access and Transforming Health (PATH); Capacity and Infrastructure Transition, Expansion and Development (CITED) Initiative, SAC Health will increase the number of Enhanced Care Management teams by four, resulting in 10 teams, serving over 2,000 patients at any given time.

Enhanced Care Management is a whole-person, interdisciplinary approach to care that addresses the clinical and non-clinical needs of eligible Medi-Cal Members who have the most complex medical and social needs. It allows for a systematic coordination of services and comprehensive care management that is personal, community-based, and multi-disciplinary. SAC Health implemented Enhanced Care Management in (given year) through funding from Inland Empire Health Plan (IEHP).

“SAC Health implemented Enhanced Care Management in 2017 with the financial support of IEHP,” notes Jason Lohr, MD, CEO of SAC Health. “We have seen first-hand, how effective it is in helping individuals who have the most complex healthcare needs. Thanks to the California Department of Health Care Services and IEHP, SAC Health will be able to expand access to Enhanced Care Management for our patients.”

SAC Health is a Federally Qualified Health Center with twelve locations throughout the Inland Empire. Serving over 50,000 patients in 2022, with over 97 percent being at or below 200 percent of the Federal Poverty Line, SAC Health is a safety-net clinic providing high quality patient-centered care throughout the region.

About SAC Health

SAC Health is the largest specialty-based and teaching health center (THC) Federally Qualified Health Center (FQHC) in the nation. SAC Health provides comprehensive services to underserved areas and populations including Medi-Cal and Medicare patients. SAC Health is recognized as a Level-3 Patient-Centered Medical Home by the National Committee for Quality Assurance (NCQA) and has over 100 community partnerships that enable the health to provide whole-person care to all its patients. SAC Health provides care in 12 locations, along with a mobile clinic, in San Bernardino and Riverside counties, including services in family medicine; pediatrics and pediatric specialties; obstetrics and gynecology, internal medicine and medical specialties; family dentistry; behavioral health; surgical specialties and more. More information on how to become a patient at SAC Health is available online at sachealth.org.

Share article on social media or email:

iuvo BioScience Hires Industry Executive to Lead Commercial Organization


Sanjeev will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth.

iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical and medical device customers, today announced it has hired Sanjeev Ganatra, MBA, as their Chief Commercial Officer. This hire demonstrates iuvo’s continued commitment to client service, differentiated expertise, and investment in the business to support the company’s growth trajectory.

Ganatra is a well-established operational and business executive who brings years of experience in sales, marketing, business and corporate development both in pharma service companies as well as commercial organizations. Ganatra spent his early years in pharmaceutical and medical device development organizations before moving into the pharma services business. He spent three years with a global ophthalmic CRO, and most recently was the SVP of Sales and Marketing and Global Head of Ophthalmology at CBCC Global Research.

Ganatra is excited about joining the iuvo team, stating, “The journey that has led iuvo to its current level of success is attributed to the combination of a great team, excellent service, and collaborative clients. My goal is to help further build on this platform, creating new opportunities for our team to demonstrate their talent and for our clients to have a comprehensive partner for their development needs.”

Daniel Spasic, Board Chair of iuvo BioScience, offered his welcome as well, “We’ve all been impressed by Sanjeev’s accomplishments in sales and customer service, as well as his deep understanding of operational aspects in executing ophthalmology trials. He will be welcomed into a fast-paced ophthalmology business that span services from pre-clinical, scientific consulting and clinical development, where his contribution will be essential to our continued growth.”

Ben Burton, CEO of iuvo BioScience, provided these final comments, “As we enter the next phase of our company, Sanjeev will play an important role in our PROTM (Partner Research Organization) Model as we continue to serve clients across the globe. Sanjeev’s demonstrated expertise in client service is a perfect cultural fit for our team, and his business acumen and performance track record will create value immediately for iuvo BioScience. We are excited to have Sanjeev on-board.”

About iuvo BioScience

Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company’s facility features laboratories for analytical chemistry, microbiology, pharmacology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company’s Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Additional information about iuvo is available at http://www.iuvobioscience.com

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit http://www.ampersandcapital.com or follow us on LinkedIN at https://www.linkedin.com/company/ampersand-capital-partners/.

Share article on social media or email:

NexCore Group breaks ground on Intermountain Health Aurora Crossroads Campus Medical Office Building


Officials of NexCore Group and Intermountain Health break ground

Officials of NexCore Group and Intermountain Health were on hand for the Mar. 21st ground breaking event.

The Aurora Crossroads Medical Campus will become the epicenter of healthcare in the area as part of Intermountain Health’s robust ambulatory care network strategy.

Denver-based NexCore Group, a nationally recognized healthcare real estate investment and development company, broke ground on a new medical office building for Intermountain Health (formerly SCL Health) on their Aurora Crossroads campus March 21, 2023. The three-story, 85,000 square foot facility is conveniently located at the intersection of E-470 and I-70 in north Aurora and is projected to open in the second quarter of 2024.

“NexCore is excited to provide a facility designed to provide quality, comprehensive care in this fast-growing area,” said Tom Kelly, Senior Vice President, Real Estate Development for NexCore. “The Aurora Crossroads Medical Campus will become the epicenter of healthcare in the area as part of Intermountain Health’s robust ambulatory care network strategy.”

The new medical office building will increase patient access to care in the area, housing comprehensive services including 8 primary care physicians, diagnostic imaging, lab, an ambulatory surgery center, an endoscopy center, and a variety of specialists such as OB/GYN, Orthopedics, General Surgery, and Cardiology. Plans also include proposed connectivity to the future hospital.

NexCore was selected by Intermountain Health through a competitive process to execute on their vision to expand into the Aurora market, providing patients with a differentiated, integrated care experience. “This is the perfect opportunity for NexCore to deliver a healthcare facility that brings excellence, convenience and comprehensive care to the community,” remarks Todd Varney, NexCore’s Chief Development Officer and Managing Partner. “At NexCore we build better outcomes – better outcomes for our health system providers, patients, and the surrounding community – and there’s no place we would rather deliver on that promise than in the area surrounding our headquarters.”

For a video of the Intermountain Health Aurora Crossroads Medical Office Building ground break please visit: https://vimeo.com/nexcoregroup/imhauroragb

Limited space is still available for lease to complementary independent physicians. For leasing information, please contact Kristen Neumann at kristen.neumann@nexcoregroup.com or 303-710-1909.

For more information or for comment, please contact Kirstin Barbour at kirstin.barbour@nexcoregroup.com or 303-501-6713.

NexCore Group LLC is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning, and managing purpose-built facilities for healthcare, senior living, and science and technology. Since its founding in 2004, NexCore has successfully completed over $5.5 billion in real estate transactions throughout 25 states, developed and acquired over 15.2 million square feet of healthcare, science, and senior living communities, and currently manages over $3.3 billion in assets spanning 7.6 million square feet. NexCore is headquartered in Denver, with regional offices in Bethesda, Charlotte, Dallas, Detroit, Houston, Indianapolis, Los Angeles, Orlando, Phoenix, and Seattle.

Share article on social media or email:

hyperCORE International Appoints Carlos E. Orantes as New Chairman of Executive Board


Carlos E. Orantes portrait

Carlos E. Orantes Appointed Chairman of hyperCORE Executive Board

“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one.” – Carlos E. Orantes, CEO of Alcanza Clinical Research

hyperCORE International has announced the appointment of Carlos E. Orantes, CEO of Alcanza Clinical Research, as Chairman of the hyperCORE Executive Leadership Board. Effective April 2023, Orantes succeeds Mark Lacy, who has served as Chairman since the super network’s inception in 2019.

“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one,” said Orantes. “The passion for delivering strong clinical research is palpable amongst all my hyperCORE colleagues, which will make this role extremely fulfilling for me both personally and professionally.”

Orantes, who has worked in drug development for almost 30 years, continues to serve as CEO of Alcanza Clinical Research. His efforts have been focused on building capable teams and leading them through transformations at several successful small to large companies, privately and publicly held. He is passionate about empowering team members and holding to a high standard of delivering on commitments.

“hyperCORE takes great pride in having each of its members actively supporting this wonderful super network,” said Karri Venn, CEO of hyperCORE and COO at Centricity Research. “Carlos Orantes is stepping into this role as one of the newer members of hyperCORE and is eager to do his part to support the continued growth and objectives we have set out for our group. I am incredibly excited to work with him and appreciate the passion he is bringing to this position.”

“It has been an absolute honor working with Mark Lacy as Chairman for the past two years,” Venn continued, “and Benchmark Research will continue to be a part of the hyperCORE network.” Lacy is the Founder and CEO of Benchmark Research, a growing and dynamic network of quality clinical research sites throughout the United States that is also a founding alliance partner of hyperCORE International.

Share article on social media or email:

How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases, Upcoming Webinar Hosted by Xtalks


HIV/AIDS and malaria remain major public health problems worldwide.

The World Health Organization (WHO) reports that: 2.3 million people living with HIV in the WHO European Region have been infected with the virus over the past 40 years; In 2021, nearly 80 percent of all deaths were due to malaria in the WHO African Region.

These numbers indicate that HIV/AIDS and malaria remain major public health problems worldwide.

In this webinar, attendees will learn about the strategic potential of humanized mice in the search for treatments for these infections.

In the first part, featured speaker Dr. Sebastien Tabruyn, will discuss how the human immune system responds to infection in a humanized CD34-NCG mouse model, the preclinical analysis toolkit of the HIV platform and how the humanized model allows for the evaluation of drug candidates, especially for infectious diseases.

In the second part, featured speaker Dr. Iñigo Angulo-Barturen, will discuss the humanized Plasmodium falciparum mouse model for the study of human malaria and in vivo evaluation of new antimalarial drugs. He will present the characteristics of the humanized P. falciparum asexual blood stage (ABS) mouse models available at the drug discovery company TAD, their use as tools to study the development of resistance during suboptimal treatment regimens and the efficacy of monoclonal antibodies and drugs against susceptible and resistant strains.

Register today to find out how humanized mice models can accelerate preclinical studies in infectious diseases such as malaria and HIV.

Join Dr. Sebastien Tabruyn, PhD CSO, TransCure bioServices; and Iñigo Angulo-Barturen, PhD, CEO, The Art of Discovery SL, for the live webinar on Tuesday, April 25, 2023, at 11am EDT (5pm CEST/EU-Central).

For more information, or to register for this event, visit How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Mount Sinai Achieves Highest Rating From Society of Thoracic Surgeons for Ground-Breaking Esophagectomy Program


“Focusing on the fine points of an operation is what actually gets rid of the cancer and helps ensure that the patient will recover without a complication,” said Dr. Raja Flores, chair of thoracic surgery at the Mount Sinai Health System.

The Mount Sinai Health System’s esophagectomy program has received a three-star (excellent performance) overall composite score from the Society of Thoracic Surgeons (STS).

According to STS, only 13 institutions in the United States and Canada hold the three-star rating, which denotes the highest category of quality, for esophagectomy surgery. The esophagectomy overall performance score represents two domain scores in a single number: absence of both operative mortality and major morbidity.

Esophagectomy is the main surgical treatment for esophageal cancer. Mount Sinai’s esophagectomies incorporate a surgical innovation by Raja Flores, MD, Chair of Thoracic Surgery at the Mount Sinai Health System, who pioneered a simple yet highly effective change in the surgical approach.

“I’m surprised and honored at the recognition our department has received from the STS,” Dr. Flores said. “Surprised because it has been my hope that surgeons at other institutions would adopt our modification, which simply involves switching the juncture site between the stomach and the esophagus to promote better blood flow between the two organs.” Dr. Flores described the revision in an article in the Journal of Surgical Oncology and created a video to demonstrate the technique.

The revised procedure is less invasive than conventional esophagectomy, causes less trauma, and reduces complications such as leaking or obstruction. It also decreases the average surgical time from seven to 2.5 hours, according to the journal article.

Many esophageal cancer patients have suffered for years from heartburn and acid reflux, and deal with the symptoms by taking antacids, Dr. Flores noted. Lou Martinez, an overnight custodian for the New York court system, was among them. One night several years ago, Mr. Martinez was having dinner at work and found that the food wouldn’t go down; it stuck in his throat. Even water just sat there.

“We diagnosed him with esophageal cancer, and like many other patients, he was shocked that a common symptom like heartburn could lead to a serious condition like cancer,” Dr. Flores recalled. Mr. Martinez, one of approximately 19,000 patients diagnosed with esophageal cancer annually in the United States, underwent the revised esophagectomy several years ago and continues to do well.

What drew Dr. Flores to thoracic surgery? “Actually, thoracic surgery chose me,” he said. “I didn’t know anything about the field until I was a fourth-year surgery resident in the ‘90s. I started seeing some patients who were a little rough around the edges, who suffered from self-inflicted exposures like alcohol addiction or smoking. I treated them at a time when esophagectomy was a dreaded procedure, when patients would have complications right and left. As I treated them, I realized I really love this field.”

Incremental changes have made esophagectomy much safer and more effective since then, and Dr. Flores hopes his approach will continue to move the field forward. “It’s not about whether you use a robot or laser or some other tool,” he said. “Focusing on the fine points of an operation is what actually gets rid of the cancer and helps ensure that the patient will recover without a complication.”

The STS star rating system is one of the most sophisticated and highly regarded overall measures of quality in health care, rating the benchmarked outcomes of cardiothoracic surgery programs in the United States and Canada. The General Thoracic Surgery Database (GTSD) star ratings are derived by testing whether the participant’s composite or domain score is significantly different from the overall STS average for esophagectomy for esophageal cancer performed by GTSD participants.

STS General Thoracic Surgery Public Reporting offers a comparison of GTSD and national outcomes, demonstrating the high performance of GTSD participants. The latest analysis of data for esophageal cancer resection covers a three-year period, from July 1, 2019, to June 30, 2022, and includes 101 participants.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Upneeq® Wins “Best Eye Drop for Drooping Lids” New Beauty In 13th Annual Beauty Awards


Upneeq®, 2023 New Beauty award winner for “Best Eyedrop for Drooping Lids”

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, M.D., PhD, a board-certified Aesthetic Reconstructive and Oculoplastic Specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “It can work in one or both ptotic eyes in as little as five minutes…”

RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the “Best Innovation” in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.

Over 10,000 products were submitted for the 2023 awards with 399 selected. Each winning product was proven to both effectively solve an aesthetic concern and meet rigorous testing standards by the NewBeauty editorial team along with an independent panel of key opinion leaders, top medical and industry professionals as well as advisors.

According to NewBeauty Features Editor, Tatiana Bido “Upneeq couldn’t be any easier to use.” She also called it an instant eyelid-lifter for ptosis or low-lying lids during their testing process.

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, M.D., PhD, a board-certified Aesthetic Reconstructive and Oculoplastic Specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “It can work in one or both ptotic eyes in as little as five minutes giving the eyes a more open looking appearance. With the drop we see an average eyelid elevation between 1 and 2 millimeters which is truly significant.”

“We are incredibly proud to be acknowledged for a second year by NewBeauty with this prestigious award,” said Brian Markison, Chief Executive Officer of RVL Pharmaceuticals. “We are building a new market where Upneeq has been an exciting innovation for eyelids – as the first Rx treatment for low-lying lids in adults. As we continue to build the brand in the medical aesthetics field, this recognition from the industry’s leading authority is compelling and beneficial validation.”

Upneeq® received FDA approval in July 2020 and was introduced as the only non-surgical therapeutic approved for acquired ptosis (low-lying lids) in adults. First-in-class, Upneeq® is a safe and effective, fast acting, daily treatment for patients at eye care and medical aesthetic practices nationally.

In clinical trials, Upneeq® demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. For more information and for the complete Important Safety Information, visit http://www.upneeq.com

IMPORTANT SAFETY INFORMATION

What is UPNEEQ?

UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.


What are the most common side effects of UPNEEQ?

  • The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

What should my doctor know about before prescribing me UPNEEQ?

  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.

To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit http://www.fda.gov/medwatch.

This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

About NewBeauty / NewBeauty Awards

The highly regarded industry and consumer publication, NewBeauty is published by Sandow Media. NewBeauty is the ultimate resource redefining the beauty space with its trend-driven approach to content combining authoritative experts, education and advances in industry innovation. Filled with NewBeauty editors’ trusted voices, the magazine provides an in-depth and comprehensive look at new products and breakthrough technologies with a split reputation of scientifically accurate expert-driven original reporting with ethically balanced editorial resources. NewBeauty offers a highly- curated group of winners in the annual NewBeauty Awards. Product winners of the NewBeauty Awards Seal must effectively deliver on their claims, solve aesthetic concerns, and fulfill the rigorous testing process of editors and experts.

Share article on social media or email: